Alpharma Previews First Quarter 2001 Results Also Updates Outlook For Full Year 2001

Apr 19, 2001, 01:00 ET from Alpharma Inc.

    FORT LEE, N.J., April 19 /PRNewswire/ -- Alpharma Inc. (NYSE:   ALO), a
 growing specialty pharmaceutical company with global leadership positions in
 products for humans and animals, today previewed financial results for the
 first quarter and updated its outlook for the full year 2001.  Actual results
 for the first quarter will be reported on April 30, 2001.
     Based on preliminary results, the company expects to report increased
 revenue and net income for the first quarter ended March 31, 2001, but taking
 into account the significantly higher number of shares outstanding, the
 company will not achieve its estimated earnings per share for the quarter of
 approximately 15 percent over last year's reported $.33.  The company expects
 that earnings per share for the first quarter of 2001 will be $.26 to $.28 per
 share.
     Alpharma previously disclosed factors that would have a significant
 negative effect on first half 2001 results.  These factors were the impact on
 the Company's International Pharmaceutical Division of lower U.K. pricing and
 the impact on the Company's Animal Health Division of the softness in poultry
 and livestock markets and delays in launching new animal health products.
     Preliminary results for the first quarter of 2001 indicate that these
 factors are having a more severe effect on earnings than previously estimated
 and are the primary reason that earnings per share for the first quarter are
 expected to be below the Company's previous estimate.
 
     Current Outlook
     Based upon the first quarter preliminary results, the Company has re-
 evaluated its view of the estimated future impact of the factors that affected
 the International Pharmaceutical and Animal Health Divisions.  The Company now
 estimates that these factors will have a more significant impact in the first
 six months and will extend into the second half of 2001.  As a result, the
 Company now estimates that while revenue for the full year should be over $1
 billion and net income is expected to rise by over 20 percent to approximately
 $75 million, considering the higher number of shares outstanding in 2001,
 earnings per share will be about $ 1.70 per share.  For the second quarter of
 2001, the Company estimates that earnings per share will approximate that
 achieved in the first quarter of 2001.
     Commenting on the announcement, Ms. Ingrid Wiik, President and Chief
 Executive Officer of Alpharma said, "We are building Alpharma toward global
 leadership in human generic and animal pharmaceuticals.  We are convinced that
 we are creating a Company with long term, sustainable growth through the
 consistent execution of our strategy.  Since the adoption of this basic
 strategy in 1997, we have strengthened Alpharma and through 2000 achieved
 compound annual growth in earnings per share of 30 percent.  While it is now
 apparent that the factors we have disclosed will have a significant impact on
 our financial results this year, we have chosen not to abandon the pursuit of
 our strategy."
     Alpharma management will conduct a conference call on Friday, April 20,
 2001, beginning at 8:30 AM Eastern Daylight Time to discuss the contents of
 this press release.
     The call will be open to all interested parties including analysts,
 institutional investors, individuals and the media.  The call may be accessed
 by using the following information:
 
     CONFERENCE CALL ACCESS
     Domestic Dial In:       800-562-8369
     International Dial In:  913-981-5581
     Participant Code:       738150
 
     In addition, for those unable to participate at the time of the call, a
 rebroadcast will be available following the call from Friday, April 20, 2001
 at 7:00 PM Eastern Daylight Time until Friday, April 27, 2001 at midnight.
 The rebroadcast may be accessed by telephone using the following information:
 
     REBROADCAST ACCESS
     Domestic Dial In:          888-203-1112
     International Dial In:     719-457-0820
     Participant Code:          738150
 
     Alpharma Inc. (NYSE:   ALO) is a growing specialty pharmaceutical company
 with global leadership positions in products for humans and animals.  Uniquely
 positioned to expand internationally, Alpharma is presently active in more
 than 60 countries.  Alpharma is the largest manufacturer of generic liquid and
 topical pharmaceuticals in the U.S. and one of the largest manufactures of
 generic solid dose pharmaceuticals in Europe, with a growing presence in
 Southeast Asia.  Alpharma is among the world's  leading producers of several
 important pharmaceutical-grade bulk antibiotics and is internationally
 recognized as a leading provider of pharmaceutical products for poultry,
 seine, cattle, and vaccines for farmed-fish worldwide.
 
     Statements made in this press release include forward-looking statements
 made pursuant to the safe harbor provisions of the Security Litigation Reform
 Act of 1995.  Such statements, including those relating to financial
 expectations for the year 2001, involve certain risks and uncertainties that
 could cause actual results to differ materially from those in the forward
 looking statements.  Information on other significant potential risks and
 uncertainties not discussed herein may be found in the Company's filing with
 the Securities and Exchange Commission including its Form 10-K for the year
 ended December 31, 2000.
 
     All Alpharma press releases are also available at our
 website -- http://www.alpharma.com
     If you would like to receive future Alpharma press releases via email
 please contact: investorrelations@alpharma.com.
 
 

SOURCE Alpharma Inc.
    FORT LEE, N.J., April 19 /PRNewswire/ -- Alpharma Inc. (NYSE:   ALO), a
 growing specialty pharmaceutical company with global leadership positions in
 products for humans and animals, today previewed financial results for the
 first quarter and updated its outlook for the full year 2001.  Actual results
 for the first quarter will be reported on April 30, 2001.
     Based on preliminary results, the company expects to report increased
 revenue and net income for the first quarter ended March 31, 2001, but taking
 into account the significantly higher number of shares outstanding, the
 company will not achieve its estimated earnings per share for the quarter of
 approximately 15 percent over last year's reported $.33.  The company expects
 that earnings per share for the first quarter of 2001 will be $.26 to $.28 per
 share.
     Alpharma previously disclosed factors that would have a significant
 negative effect on first half 2001 results.  These factors were the impact on
 the Company's International Pharmaceutical Division of lower U.K. pricing and
 the impact on the Company's Animal Health Division of the softness in poultry
 and livestock markets and delays in launching new animal health products.
     Preliminary results for the first quarter of 2001 indicate that these
 factors are having a more severe effect on earnings than previously estimated
 and are the primary reason that earnings per share for the first quarter are
 expected to be below the Company's previous estimate.
 
     Current Outlook
     Based upon the first quarter preliminary results, the Company has re-
 evaluated its view of the estimated future impact of the factors that affected
 the International Pharmaceutical and Animal Health Divisions.  The Company now
 estimates that these factors will have a more significant impact in the first
 six months and will extend into the second half of 2001.  As a result, the
 Company now estimates that while revenue for the full year should be over $1
 billion and net income is expected to rise by over 20 percent to approximately
 $75 million, considering the higher number of shares outstanding in 2001,
 earnings per share will be about $ 1.70 per share.  For the second quarter of
 2001, the Company estimates that earnings per share will approximate that
 achieved in the first quarter of 2001.
     Commenting on the announcement, Ms. Ingrid Wiik, President and Chief
 Executive Officer of Alpharma said, "We are building Alpharma toward global
 leadership in human generic and animal pharmaceuticals.  We are convinced that
 we are creating a Company with long term, sustainable growth through the
 consistent execution of our strategy.  Since the adoption of this basic
 strategy in 1997, we have strengthened Alpharma and through 2000 achieved
 compound annual growth in earnings per share of 30 percent.  While it is now
 apparent that the factors we have disclosed will have a significant impact on
 our financial results this year, we have chosen not to abandon the pursuit of
 our strategy."
     Alpharma management will conduct a conference call on Friday, April 20,
 2001, beginning at 8:30 AM Eastern Daylight Time to discuss the contents of
 this press release.
     The call will be open to all interested parties including analysts,
 institutional investors, individuals and the media.  The call may be accessed
 by using the following information:
 
     CONFERENCE CALL ACCESS
     Domestic Dial In:       800-562-8369
     International Dial In:  913-981-5581
     Participant Code:       738150
 
     In addition, for those unable to participate at the time of the call, a
 rebroadcast will be available following the call from Friday, April 20, 2001
 at 7:00 PM Eastern Daylight Time until Friday, April 27, 2001 at midnight.
 The rebroadcast may be accessed by telephone using the following information:
 
     REBROADCAST ACCESS
     Domestic Dial In:          888-203-1112
     International Dial In:     719-457-0820
     Participant Code:          738150
 
     Alpharma Inc. (NYSE:   ALO) is a growing specialty pharmaceutical company
 with global leadership positions in products for humans and animals.  Uniquely
 positioned to expand internationally, Alpharma is presently active in more
 than 60 countries.  Alpharma is the largest manufacturer of generic liquid and
 topical pharmaceuticals in the U.S. and one of the largest manufactures of
 generic solid dose pharmaceuticals in Europe, with a growing presence in
 Southeast Asia.  Alpharma is among the world's  leading producers of several
 important pharmaceutical-grade bulk antibiotics and is internationally
 recognized as a leading provider of pharmaceutical products for poultry,
 seine, cattle, and vaccines for farmed-fish worldwide.
 
     Statements made in this press release include forward-looking statements
 made pursuant to the safe harbor provisions of the Security Litigation Reform
 Act of 1995.  Such statements, including those relating to financial
 expectations for the year 2001, involve certain risks and uncertainties that
 could cause actual results to differ materially from those in the forward
 looking statements.  Information on other significant potential risks and
 uncertainties not discussed herein may be found in the Company's filing with
 the Securities and Exchange Commission including its Form 10-K for the year
 ended December 31, 2000.
 
     All Alpharma press releases are also available at our
 website -- http://www.alpharma.com
     If you would like to receive future Alpharma press releases via email
 please contact: investorrelations@alpharma.com.
 
 SOURCE  Alpharma Inc.